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Umbilical cord mesenchymal stromal cells (MSC) have been widely investigated for cell-based therapy studies as an alternative
source to bone marrow transplantation. Umbilical cord tissue is a rich source of MSCs with potential to derivate at least muscle,
cartilage, fat, and bone cells in vitro. The possibility to replace the defective musclecells using cell therapy is a promising approach
forthe treatment ofprogressive musculardystrophies (PMDs),independently ofthe speciﬁc gene mutation.Therefore, preclinical
studiesindiﬀerent modelsofmusculardystrophiesareofutmostimportance. Themainobjective ofthepresent studyistoevaluate
if umbilical cord MSCs have the potential to reach and diﬀerentiate into muscle cells in vivo in two animal models of PMDs. In
order to address this question we injected (1) human umbilical cord tissue (hUCT) MSCs into the caudal vein of SJL mice; (2)
hUCTandcanineumbilicalcordvein(cUCV)MSCsintra-arteriallyinGRMDdogs.Ourresultsherereported supportthesafetyof
theprocedure andindicate that theinjected cells could engraft in thehost musclein both animalmodels but could not diﬀerentiate
into muscle cells. These observations may provide important informationaiming future therapy for muscular dystrophies.
1.Introduction
Mesenchymal stromal cells (MSCs) have been extensively ex-
plored over the last years to understand their stem cell prop-
erties and clinical application. MSCs were ﬁrst isolated from
bone marrow (BM), but similar populations have been re-
ported afterwards in other tissues, such as adipose tissue,
dental pulp, placenta, umbilical cord, and fallopian tube [1–
4]. They comprise a population of cells with ability to self-
renew and diﬀerentiate into speciﬁc functional cell types
including chondrocytes, osteocytes, adipocytes, and myo-
cytes in vitro. However, examining the diﬀerentiation poten-
tial of MSCs in vivo still stands as one of the most important
waytoaddresstheirstemnesscapacityanddirecttheirusefor
future cell-based therapies.
Among the genetic diseases of great medical relevance
aretheprogressive musculardystrophies (PMDs),aclinically
and genetically heterogeneous group of disorders for which
there is no cure. They are caused by the deﬁciency or abnor-
mal muscle proteins, resulting in progressive degeneration
and loss of skeletal muscle function [5]. Duchenne muscular
dystrophy (DMD), which aﬀects 1 in 3500 male births,
is the most common and severe form. It is caused by
mutations in the dystrophin gene leading to the absence of
the muscle dystrophin protein, an essential component of
skeletal muscle [6]. The clinical course of DMD is severe and
progressive. Aﬀected individuals exhibit muscular weakness
by the age of 5 years, lose their independent ambulation
around12years, and,withoutspecialcare,theysuccumbdue
to respiratory failure or cardiomyopathy in their late teens or
early twenties [5].
The murine model for DMD, the mdx mouse, also lacks
muscle dystrophin. However, in opposition to aﬀected boys,
they have an almost normal phenotype [7, 8]. On the other
hand, the golden retriever muscular dystrophy dog (GRMD)
has a frameshift point mutation within the splice acceptor2 Journal of Biomedicine and Biotechnology
site in intron 6 of the dystrophin gene, which results in the
complete absence of the muscular protein [9]. Although the
disease course is variable, and neonatal death is frequent,
with very rare exceptions [10], GRMD dogs are severely af-
fectedand representthebestanimal modelforhumanDMD.
Diﬀerently from DMD, the limb-girdle muscular dystro-
phies (LGMDs) constitute a subgroup of 22 diﬀerent forms
identiﬁed until now, most of them with autosomal recessive
inheritance [11, 12]. They are characterized by the involve-
ment of the pelvic and shoulder girdle musculature. Among
the autosomal recessive forms, one of the most prevalent is
caused by mutations in the dysferlin gene resulting in two
phenotypes: miyoshi myopathy (MM) which aﬀects distal
muscles at onset, with preferential early involvement of the
gastrocnemius and LGMD2B with a more pronounced limb-
girdle involvement [13]. Dysferlin expression is reduced or
absent in these patients [14, 15].
A 171-bp in-frame deletion in the murine dysferlin
cDNA was identiﬁed in a mouse model, the SJL mice, with
a corresponding reduction in dysferlin levels to 15% of nor-
mal. The spontaneous myopathy of the SJL mice begins at
4–6 weeks of age and is nearly complete by 8 months of age
with a progressive inﬂammatory change in muscle [16]. The
SJL mice deletion is in-frame and, therefore, does not cause
a total absence of the protein.
Adult skeletal muscle has the potential to regenerate new
muscle ﬁbers by activating a population of mononucleated
precursors, which otherwise remain in a quiescent and non-
proliferativestate [17].However, thecontinuousand gradual
muscle degeneration in progressive muscular dystrophies
leads to a depletion of satellite cells, and, consequently, the
capability to restore the skeletal muscle is lost [18, 19]. The
possibility to repair the defectivemusclethroughcell therapy
is a promising approach for the potential treatment of PMD,
independently of speciﬁc mutations.
Wehaverecentlyshown thathumanumbilicalcordtissue
(hUCT) is a rich source of MSC with ability to diﬀerentiate
into skeletal muscle cells in vitro [3, 20]. We also described
that canine MSCs could be isolated from umbilical cord
vein (cUCV) and that they represent a good candidate for
preclinical studies [21]. Human umbilical cord MSCs are
obtained after full-term delivery of the newborn, from a
sample that would be inevitably discarded. The process is
noninvasive, painless, and without harm for the mother or
the infant. These cells also lack the expression of the major
histocompatibility complex (MHC) class I and II antigens
which render them to be highly tolerated in transplantations
[22,23]and excellent candidatesforcellreplacement therapy
in PMDs.
However, it is not known if umbilical cord MSCs show
the same in vitro muscle diﬀerentiation capacity as in vivo.
In order to address this question we injected umbilical
cord MSCs in two diﬀerent animal models of PMDs, SJL
mice, and GRMD dogs, aiming to compare their ability to
engraft into the host muscle and express muscular proteins.
Although the injected cells could reach the musculature in
both animal models, they were unable to diﬀerentiate into
musclecells.InGRMDdogs,itisverydiﬃcultto evaluatethe
therapeutic eﬀect of any procedure due to their great clinical
variability. However, we observed that SJL-injected mice had
afunctionalperformancesigniﬁcantlybetterthanthecontrol
noninjected animals. These results may have important im-
plications for future therapeutic approaches.
2.Materialsand Methods
2.1.EthicsStatement. Thisstudywasapprovedbythehuman
research ethics committee (Comitˆ ed e´ etica em pesquisa—
seres humanos—CEP) and by the animal research ethics
committee (Comiss˜ ao de ´ etica no uso de animais em ex-
perimentac ¸˜ ao—CEUA)of Institute ofBioscienceand Univer-
sity Hospital of University of S˜ ao Paulo. hUCT MSC were
collected from donated umbilical cord (UC) units, after all
mothers sign the written informed consent, in accordance
with the ethical committee of Institute of Bioscience and
University Hospital of University of S˜ ao Paulo (CEP), per-
mit number 040/2005. Animal care and experiments were
performed in accordance with the animal research ethics
committee (CEUA)ofthe BiosciencesInstitute, University of
S˜ ao Paulo, permit number 034/2005.
2.2. Animal Models. SJL mice were purchased from the Jack-
son Laboratory. The GRMD dog colony was established with
a female GRMD carrier, Beth, donated by Dr. Joe Kornegay
(University of North Carolina). All animals were housed and
cared for in the University of Sao Paulo.
GRMD dogs were genotyped, at birth, from blood ge-
nomic DNA extracted with the kit GFX Genomic (GE
Healthcare). For PCR reaction, the primers GF2 and GR2
and the temperature conditions were used as previously re-
ported [24]. DMD diagnosis was conﬁrmed by the digestion
of PCR products with the enzyme Sau96I (New England Bi-
olabs) and by elevated serum creatine kinase (CK) levels.
Dogleukocyteantigen(DLA)-identicallittermatedonor/
recipient pairs were determined based on the identity for
highly polymorphic MHC class I (C.2200) and MHC class II
(C. 2202) microsatellite markers, formerly described [25].
2.3. Harvesting and Expansion of hUCT and cUCV MSC.
Human umbilical cord (UC) units were collected and trans-
ferred to the laboratory under sterile conditions. hUCT
and cUCV were isolated, characterized, and expanded as
described elsewhere [3, 21]. Brieﬂy, UC of full-term deliv-
eries were ﬁlled with 0.1% collagenase (Sigma-Aldrich) in
phosphate-buﬀered saline (PBS, Gibco) and incubated at
37◦C for 20 minutes. Then, each UC was washed inter-
nally with proliferation medium consisting of Dulbecco’s
modiﬁed Eagle’s medium-low glucose (DMEM-LG; Gibco)
supplemented with 10% of fetal bovine serum (FBS; Gibco).
Detached cells were harvested after gentle massage of the
umbilical cord and centrifuged at 300g for 10 minutes. Cells
wereresuspendedinproliferationmedium,seededin25-cm2
ﬂasks, and maintained at 37◦C in a humidiﬁed atmosphere
containing 5% CO2. After 24 hours of incubation, nonad-
herent cells were removed, and culture mediumwas replaced
every3days.Adherentcellswere cultureduntilreaching 90%
conﬂuence and passaged using TrypLE (Invitrogen).Journal of Biomedicine and Biotechnology 3
2.4. Cell Transplantation
2.4.1. SJL Mice. Two-month-old SJL mice were divided into
two groups (n = 7): experimental (group A) and control
(group B). Each animal from group A was injected in the tail
veinwith 1×106 ofhUCTMSCsin0.1mLofHank’sBuﬀered
Salt Solution(HBSS,Gibco). The animals were injected for 6
months, weekly in the ﬁrst month and then monthly. The
control group B were uninjected animals. All results were
analyzed blindly. The code for each of the mice groups was
disclosed only after the completion of all the studies. Two
months after the last cell transplantation, the animals were
euthanatized using a CO2 chamber.
2.4.2. GRMD Dogs. Approximately 1 × 107 cUCV or hUCT
cells were injected through the femoral artery of 3 GRMD
dogs. Dogs were sedated, and the injections were performed
using a 22 gauge intravenous catheter connected to the
injection syringe containing the cells resuspended in a
ﬁnal volume of 10mL of HBSS. Transplantation protocol
started when dogs were 51-day old, and each dog received
7 consecutive injections with 30-day interval. All dogs were
given standard supportive care and have been followed up
during all experimentation. Completion time of the study
was determined when the dogs died of natural DMD-related
causes.
2.5. Muscle Biopsies. In the SJL study, muscle biopsies were
collected after animals were euthanized. Samples were taken
from distal and proximal muscles localized in the hind leg
and foreleg of both experimental and control animals.
In GRMD dogs, biopsies were obtained from biceps fe-
moralis. The ﬁrst procedure (B144) was realized two days
after the third injection, when dogs were 144-day old.
The second procedure (B312) was done 3 days after the
seventhinjection,when dogswere 312daysold.Duringthese
procedures, the animals were under eﬀect of anesthesia and
sedation.
Each biopsy was divided into two pieces. The ﬁrst piece
was reserved for histological analysis and prepared by em-
bedding in optimal cutting temperature compound and
stocked in liquid nitrogen. The other fragment was used for
molecular analysis and prepared by snap freezing in liquid
nitrogen.
2.6. Engraftment Analysis. DNAsamples were obtained from
muscle biopsies using DNeasy Blood & Tissue Kit (Qiagen).
The presence of human DNA in the host was evaluated as
described in Pelz et al. [26].
T od e t e c tt h ep r e s e n c eo fYc h r o m o s o m ei nt h ef e m a l e -
injected animals, we evaluated the ampliﬁcation of the sex-
determining region Y (SRY) gene by PCR using the primers
and temperature conditions previously described [27]. PCR
productswere separated by electrophoresis on6% polyacryl-
amide gels and stained with ethidium bromide. Nonsatu-
rated digital images were obtained using ImageQuant imag-
ing system (GE HealthCare).
2.7. Protein Analysis. Immunohistochemistry (IHC) and
western blot (WB) were performed according to the meth-
odologies previously described [28]. The following pri-
mary antibodies were used: antidystrophin NCL-DYS1 and
NCL-DYS2 (Novocastra Laboratories); speciﬁc antihuman-
dystrophin MANDYS106 2C6 and MANDYS108 4D8 (a
kind gift from Dr. Glenn Morris and Dr. Nguyen thi Man,
from the North East Wales Institute, Wrexham, UK);speciﬁc
antihuman nuclei MAB1281 (Chemicon).
For IHC, samples were incubated with antimouse IgG-
Cy3-conjugated secondary antibody (Chemicon), and, when
necessary, slides were counterstained with 4 ,6 - d i a m i d i n o -
2phenylindole (DAPI; Sigma). Slides were examined in Axi-
overt 200 microscope (Carl Zeiss), and imageswere captured
using Axiovision 3.1 software (Carl Zeiss).
For WB, horseradish peroxidase (HRP)-conjugated anti-
mouse secondary antibody (Santa Cruz Biotechnology) was
used to detect immunoreactive bands with enhanced chemi-
luminescence (ECL) plus kit (GE Healthcare).
2.8. Functional Assessment. In order to verify whether inject-
ed hUCT MSCs would improve motor ability in SJL-injected
mice, we performed motor ability tests before and after 2
months of the last injection. Mice were examined, weighed,
and submitted to the following tests: (a) the inclined plane
test evaluated by measuring the maximal angle of a wood
board on which the animal was placed until it slipped; (b)
t h ew i r eh a n g i n gt e s tto determine the ability of the mouse
suspended on a horizontal thread by its forelegs, to reach it
with its hind legs and the length of time they were able to
stay hanging; (c) the ambulation test which was performed to
determine the mean length of a step measured in hindfoot
ink prints while mice freely run in a corridor (length: 50cm;
width: 8cm; height of lateral walls: 20cm) [29].
2.9. Statistical Analysis. Observations were quantiﬁed blind-
ly. Numerical data are the mean ± sd (standard deviation).
The statistical analysis of the equivalence between the
injected and uninjected mice was achieved by the one-
tailed Student’s t-test, at the signiﬁcance level of P = 0.05,
and the results were expressed by the percentage variation
between their performance before and after hUCT MSC
transplantation.
3.Results
3.1. DMD Typing, DLA Matching of Littermates and Trans-
plantation Setup. For this study, we had 3 aﬀected GRMD
dogs available from same litter: 1 aﬀected male, L3M6;
two aﬀected females, L3F1 and L3F2. However, only the
dogs L3M6 and L3F1 had DLA-histocompatible pairs from
the male littermates L3M7 and L3M5, respectively. The
donor-recipient pairs with DLA identity were chosen where
the recipients possessed the dystrophin mutation, and the
d o n o r sw e r ew i l d - t y p el i t t e r m a t e s .T h u sw ei n j e c t e dc U C V
cells from DLA-compatible donors into the dogs L3M6 and
L3F1. Since L3F2 did not have any DLA-compatible donor,
we injected this dog with male hUCT MSCs. Both cell type4 Journal of Biomedicine and Biotechnology
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Figure 1: Engraftment of male human and canine umbilical cord
MSCs into muscle of female GRMD dogs. Polymerase chain reac-
tion analysis for (a) sex-determining region Y (SRY) sequence and
(b) canine-speciﬁc dystrophin sequence. Muscles samples shown
are the following:(1) malecUCV MSC from L3M5;(2) male hUCT
MSC; (3, 4) B144 and B312 from aﬀected female L3F1; (5, 6) B144
and B312 from aﬀected female L3F2; (7) female canine control
DNA; (8) female human control DNA.
injectedwerepreviouslycharacterized byimmunophenotyp-
ing and diﬀerentiation potential [3, 21].
3.2. Capacity of Umbilical Cord MSCs to Reach and Engraft at
the Host Muscle of Transplanted Animals. In order to verify if
human and canine umbilical cord MSCs were able to reach
and colonize the host muscle, we analyzed the biopsies of
transplanted female dogs, L3F1 and L3F2, which received
male cUCVand hUCTcells respectively. By PCR analysis, we
detected the presence of the Y-chromosome marker SRY in
muscle biopsies of both aﬀected females, indicating the pres-
ence of the injected cells in the musculature of these animals
(Figure 1).Inaddition,scatteredhumancellswereconﬁrmed
in theaﬀectedfemale L3F2byimmunohistochemistry (IHC)
using speciﬁc antibody for human nuclei (Figure 2).
We also found similar results in the SJL mice model
injected with hUCT MSCs into the caudal vein [30]. PCR
analysis detected human DNA in the foreleg and hind leg
muscles of all seven injected mice (data not shown).
3.3. Muscle Proteins in Transplanted Animal Models. To ex-
plore the myogenic diﬀerentiation followed by the engraft-
ment of umbilical cord MSCs, we analyzed the expression
of dystrophin in the host muscle of transplanted GRMD
dogs. Through western blot (WB) analysis (Figure 3(a)), no
dystrophin was found in the muscles of injected animals
indicating that the engrafted cells were unable to produce
muscular proteins. In addition, we did not observe the
expression of human dystrophin, by IHC analysis (Figure 4)
or RT-PCR analysis (data not shown), in the muscle biopsies
of the aﬀected female L3F2 that received hUCT MSCs.
Three months after we ﬁnalized the injections in GRMD
animals, the dog L3M6 died of natural GRMD-related
causes. Aiming to investigate if the injected cells into the
femoral artery were able to spread all over his body, reach
diﬀerent muscular groups, and restore the dystrophin ex-
pression, we collected eight diﬀerent muscle samples at his
necropsy. However, no dystrophin expression was found by
WB analysis in any analyzed tissue (Figure 3(b)).
Similarly from what we observed in GRMD dogs, hUCT
MSCs were able to engraft in the host muscle of injected SJL
mice but were not able to diﬀerentiate into muscle cells and
express human dystrophin (data not shown) [30].
3.4. Functional Assessment. Clinical assessment in GRMD
dogs is very diﬃcult due to the great variability in their clin-
ical course [10]. From the 3 transplanted animals, one af-
fected male dog (L3M6) and one aﬀected female dog (L3F2)
died 3 months after the last cell injection at 414 days of age
andat3years and5monthsofage,respectively.However,the
female aﬀected dog L3F1 is alive at the age of 4 years.
In SJL mice, we performed three standardized motor
abilitytestsandcomparedtheirperformancebeforeandafter
cell transplantation [30]. Our results showed a statistically
signiﬁcant diﬀerence between the two groups. While unin-
jected animals worsen signiﬁcantly their performance, in the
injected group, the disease remained stable (35.14 + 9.55%
versus 13.47 ± 10%; P = 0.0014, Student’st-test, n = 7).
4.Discussion
Repairingskeletalmuscledamageisachallengeforcell-based
therapies, given the unique architecture of the tissue, which
comprises around 640 types of skeletal musclesthat make up
about40 percent ofthe body’sweight in a normal individual.
Thus, the successful use of stem cell for clinical application
in PMDs will depend on ﬁnding an easily obtainable source
that could be expanded in quantities suitable to reach the
entiremusculature,engraft,andrestore thedefectiveprotein.
Although high levels of engraftment are very diﬃcult to be
achieved, it has been reported that levels of 20–30% are able
to ameliorate dystrophic pathologic lesions [31, 32].
In the past decades, human umbilical cord has been
used as an alternative source to bone marrow for cell-based
therapies because of its hematopoietic and mesenchymal
cell components. We recently showed that hUCT is a richer
source of MSCs in comparison to human umbilical cord
blood (hUCB) [3, 20]. In addition, we demonstrated that
MSC from hUCT and hUCB have diﬀerent gene expression
proﬁles [33]. Since umbilical cord is easily obtained and a
rich source ofMSCs, we investigated their ability to originate
muscle cells in vivo and restore the expression of defective
muscular proteins in diﬀerent animal models of PMDs.
Jazedje et al. [34] and Gang et al. [35]d e m o n s t r a t e dt h a t
both hematopoietic and mesenchymal stromal cells, respec-
tively, from umbilical cord blood were able to diﬀerentiate
into skeletal muscle in vitro.I na d d i t i o n ,S e c c oe ta l .[ 3]
reported the myogenic potential, in vitro, of MSCs from
human umbilical cord tissue. Although diﬀerent cell popu-
lations from umbilical cord show apparently a similar ability
to diﬀerentiate into muscle cells at least in vitro, preclinical
studiesareofutmostimportancetoverifyifthisalsohappens
in vivo.
Kong et al. [36] injected human umbilical cord blood
cellsintravenouslyintoSJLmice.Theseauthorsreportedthat
a small number of cells engrafted in the recipient muscle
and were capable of myogenic diﬀerentiation. More recently,
Kang et al. [37] reported a boy that was cured of chronic
granulomatous disease (CGD) after being transplanted withJournal of Biomedicine and Biotechnology 5
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Figure 2: Presence of human nuclei at recipient dog muscle after umbilical cord MSCs transplantation. Scattered human cells into biceps
femoralis (B312) of aﬀected female L3F2 identiﬁed by the antihuman nuclei antibody MAB1281. Preparations were counterstained with 4 ,
6-diamidino-2phenylindole(DAPI).(a–c) humanmuscle;(d-e) nontransplantedcaninemuscle;(g-h)B312from L3F2.Insets in(g-h)show
details of human nucleus. Images were acquired with the same exposure time and magniﬁcation of 200x.
allogeneic umbilical cord blood cells. Unfortunately, two
years latter, he was diagnosed with DMD, and analysis of
his muscle biopsy demonstrated no expression of donor dys-
trophin.
In the present study, we were interested to investigate
the potential of MSCs from umbilical cord tissue for in vivo
muscle regeneration. In our ﬁrst trial, we did nine injections
of one million cells into the caudal vein of SJL mice, the
murine model of limb-girdle muscular dystrophy 2B. DNA
analysis in transplanted animals showed that the hUCT
MSCs were able to reach the host muscle through systemic
delivery. However, we did not ﬁnd human dystrophin
through WB in the same muscle samples where the human
DNA was present. In addition, the functional ability tests
did not show any clinical improvement. These results were
expectedsincethehumanumbilicalcordMSCswere notable
to originate human muscle proteins. However, surprisingly,
the performance of noninjected animals was signiﬁcantly
worse than the “treated” animals [30]. The results reported
here were done with the same methodologies used in our
previously report where we injected human adipose multi-
potent mesenchymal stromal cells (hASCs) [38]. Diﬀerently
from hUCT MSCs, hASCs injected in SJL mice resulted in
in vivo expression of human muscle proteins and functional
amelioration. These resultssuggestthatalthoughMSCsfrom
diﬀerent sources show apparently similar properties in vitro,
theym a ybem or eorles seﬃcienttodiﬀerentiateintospeciﬁc
cell lineages in vivo according to the niche where they come
from.
In thesecond trial, we used thegoldenretrievermuscular
dystrophy (GRMD) dogs, the canine model of Duchenne
Muscular Dystrophy, aiming to evaluate the ability of MSCs
from umbilical cord to regenerate the dystrophic muscle in a
large animal model using a protocol already described [39].
As reported by Sampaolesi et al. [39], intra-arterial delivery
of wild-type dog mesoangioblasts resulted in an extensive6 Journal of Biomedicine and Biotechnology
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Figure 3: Dystrophin expression analysis.Western blot using antidystrophin rod-domain DYS1 antibody. Samples shownare the following:
(a)(1)kaleidoscopeproteinstandard;(2)wild-typecaninemuscle;(3,6,9)blank;(4,5)B144andB312fromaﬀectedmaleL3M6;(7,8)B144
and B312 from aﬀected female L3F1; (10, 11) B144 and (12) B312 from aﬀected female L3F2. (b) (1) Biceps femoralis;(2) biceps brachialis;
(3) triceps brachialis; (4) quadriceps femoralis; (5) tibialis cranialis; (6) diaphragm; (7) sartorius; (8) gastrocnemius; all from aﬀected male
L3M6 at necropsy. (9) GRMD muscle; (10) wild-type canine muscle. Myosin content in the Ponceau S prestained blot was used to assess the
amount of loaded proteins.
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Figure 4: Human dystrophin expression analysis.Immunoﬂuorescence usingspeciﬁc antihuman dystrophin antibody, Mandys106/2C6.(a)
humannormalmuscle; (b) canine wild-type muscle; (c) B144 and (d) B312 from aﬀected female L3F2. Images were acquired with the same
exposure time and magniﬁcation of 200x.Journal of Biomedicine and Biotechnology 7
recoveryofdystrophinexpressionintransplanted animals.In
thepresentstudy,weinjectedsevenconsecutivesinjectionsof
onebillioncellsintothefemoralarteryofGRMDdogs.Using
the Y chromosome as a track marker, we could show the
successful engraftment of male cells into the biceps femoralis
muscle of female aﬀected dogs that received both canine
and human umbilical cord MSCs. Furthermore, human cell
engraftment into the canine muscle was also conﬁrmed
using the antihuman nuclei antibody. Similarly to what we
observed in the mouse model, human and canine umbilical
cord MSCs were able to reach the musculature in injected
aﬀected dogs, but no dystrophin expression were detected in
those animals after transplantation.
Although no relevant number of GRMD dogs were eval-
uated in preclinical cell transplantation assays by us and oth-
ers [39–41], due to the diﬃculty and high cost of such stud-
ies, its very important to test the safety and eﬃciency of
diﬀerent cell sources in a large animal model of PMD before
starting any attempt of clinical trials. In addition, since the
disease course in GRMD dogs is extremely variable, it is very
diﬃcult to analyze any amelioration or better performance
due to any preclinical study [10]. Although one of the
injected dogs did not survive long after the last injection and
one aﬀected female dog died at age of 3 years and 5 months,
we still have in our kennel in Sao Paulo one injected female
at age of 4 years that is being followed up.
In this study, we showed, in both animal models, that
even without diﬀerentiating in muscle cells, systemic injec-
tions of umbilical cord MSCs are apparently safe and may
possibly have a positive eﬀect when interacting with the host
muscle. Therapeutic eﬀects of MSCs are believed to occur
not only by direct diﬀerentiation into injured tissues but also
by productions of paracrine factors that inhibit apoptosis,
stimulate endogenous cell proliferation, and/or activate
tissue resident stem cells in the site of injury. As reported
by Prockop [42], MSCs secrete, in response to injury,
large quantities of bioactive molecules, such as cytokines,
antioxidants, proangiogenic, and trophic factors. Also, there
are growing evidences that umbilical cord MSCs possess
important immunomodulatory properties that may enable
them to survive in an allogeneic or xenogeneic environment
[43]. First, UCT MSC have low immunogenicity and sup-
press the proliferation of activated splenocytes and T cells.
Second, UCT MSC do not express human leukocyte antigen
(HLA)-DR and costimulatory molecules CD40, CD80, and
CD86 that are required for T-cell activation. Third, UCT
MSC synthesize HLA-G6, an immunosuppressive isoform of
HLAs [44–46]. Finally, UCT MSC can be tolerated in animal
models. These cells are not rejected when transplanted into
SCID mice or even as xenografts in immune-competent rats
[47–50]. As suggested by Chen et al., prostaglandin E2 is
the principal mediator of this potent immunomodulatory
property of umbilical cord MSC [51].
In short, here we analyzed, for theﬁrst time, the abilityof
mesenchymal stem cells obtained from human and canine
umbilical cord tissue to engraft into recipient dystrophic
muscle after systemic delivery, express muscle proteins in the
dystrophic host, and the safety of the procedure. Our results
showed that, in both murine and canine models of PMD,
umbilicalcordMSCswereabletoreach thehostmusculature
but were not able to complete full diﬀerentiation in skeletal
muscle cells.
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